<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598842</url>
  </required_header>
  <id_info>
    <org_study_id>H-37473</org_study_id>
    <secondary_id>6005415</secondary_id>
    <nct_id>NCT03598842</nct_id>
  </id_info>
  <brief_title>Tuberculosis - Learning the Impact of Nutrition</brief_title>
  <acronym>TB-LION</acronym>
  <official_title>Tuberculosis- Learning the Impact of Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jawaharlal Institute of Postgraduate Medical Education &amp; Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed work is based on the finding that one-third of the world is infected with the
      bacteria Mycobacterium tuberculosis (Mtb) and only 10% of these individuals develop TB. The
      study aims to identify factors that drive progression to disease and study signals (markers
      of the immune response) that detect who will progress to active TB and why this happens.
      Armed with these markers, the study will address how malnutrition and worms alter this signal
      profile to cause active TB. The work will be conducted in India, where there are 2.8 million
      TB cases each year - more than any other country - and where the government has committed to
      eliminating TB by 2035. Data suggest that malnutrition and parasites increase risk of TB
      disease so the investigators will feed malnourished household contacts and have those with
      parasites receive medication to treat these. Using this infrastructure, the investigators
      will evaluate the immunologic impact of feeding on TB pathogenesis. An additional aim is to
      understand the role of parasitic worms with the goal of determining the utility of low-cost
      ($.02 per dose) worm treatment as part of TB control efforts. Risk of developing TB will be
      evaluated for 120 household contacts of TB patients in the setting of their malnutrition and
      parasites. There are four study arms comprised of thirty participants each -- malnourished
      with parasite infection, malnourished with no parasite infection, well-nourished with
      parasite infection, and well-nourished with no parasite infection. Correlates of risk of
      disease will be assessed using blood mRNA/miRNA sequencing and T cell immune markers. The TB
      LION study will confirm that malnutrition and worms increase the risk of active TB and will
      provide the basis for effective interventions that could change the face of the TB pandemic
      and have a profound impact on the health of people worldwide. Participants in this study will
      be household contacts of tuberculosis index cases. The index cases in this study do not
      participate in the study once a household contact is established. All interventions and
      follow up are only being conducted within the household contact cohort. All intervention
      supplies, treatments, and biologics will be purchased internationally.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Enrollment suspended due to covid-19 policies.
  </why_stopped>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>Visit 1</time_frame>
    <description>Interferon Gamma -PBMC from malnourished and well-nourished HHC will be labeled with carboxyfluorescein succinimidyl ester (CFSE) and then stimulated with ESAT-6 and CFP-10 peptide libraries. After 72 hours, supernatants will be harvested and the cells analyzed by flow cytometry to monitor proliferating cells. As CFSE concentrations in a cell are halved with every cell division, each generation of cells appears as a distinct peak on the flow cytometry histogram providing a proliferative index. Supernatants will be evaluated by multiplex ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>Visit 2 (approximately 7 days after visit 1)</time_frame>
    <description>Interferon Gamma - PBMC from malnourished and well-nourished HHC will be labeled with carboxyfluorescein succinimidyl ester (CFSE) and then stimulated with ESAT-6 and CFP-10 peptide libraries. After 72 hours, supernatants will be harvested and the cells analyzed by flow cytometry to monitor proliferating cells. As CFSE concentrations in a cell are halved with every cell division, each generation of cells appears as a distinct peak on the flow cytometry histogram providing a proliferative index. Supernatants will be evaluated by multiplex ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>Visit 5 (3 months after parasite treatment / intervention initiation)</time_frame>
    <description>Interferon Gamma - PBMC from malnourished and well-nourished HHC will be labeled with carboxyfluorescein succinimidyl ester (CFSE) and then stimulated with ESAT-6 and CFP-10 peptide libraries. After 72 hours, supernatants will be harvested and the cells analyzed by flow cytometry to monitor proliferating cells. As CFSE concentrations in a cell are halved with every cell division, each generation of cells appears as a distinct peak on the flow cytometry histogram providing a proliferative index. Supernatants will be evaluated by multiplex ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Visit 6 (6 months after parasite treatment / intervention initiation)</time_frame>
    <description>Interferon Gamma - PBMC from malnourished and well-nourished HHC will be labeled with carboxyfluorescein succinimidyl ester (CFSE) and then stimulated with ESAT-6 and CFP-10 peptide libraries. After 72 hours, supernatants will be harvested and the cells analyzed by flow cytometry to monitor proliferating cells. As CFSE concentrations in a cell are halved with every cell division, each generation of cells appears as a distinct peak on the flow cytometry histogram providing a proliferative index. Supernatants will be evaluated by multiplex ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Visit 7 (12 months after parasite treatment / intervention initiation)</time_frame>
    <description>Interferon Gamma - PBMC from malnourished and well-nourished HHC will be labeled with carboxyfluorescein succinimidyl ester (CFSE) and then stimulated with ESAT-6 and CFP-10 peptide libraries. After 72 hours, supernatants will be harvested and the cells analyzed by flow cytometry to monitor proliferating cells. As CFSE concentrations in a cell are halved with every cell division, each generation of cells appears as a distinct peak on the flow cytometry histogram providing a proliferative index. Supernatants will be evaluated by multiplex ELISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurement</measure>
    <time_frame>Visit 1</time_frame>
    <description>Body Mass Index - (BMI; weight/height in kg/m2). Measurements will be taken in triplicate. Height will be measured to the nearest 0.5 cm with a stadiometer (or knee height, ulnar length or arm span [demispan] for those persons unable to stand fully erect); body weight will be measured to the nearest 0.1 kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurement</measure>
    <time_frame>Visit 5 (3 months after parasite treatment / intervention initiation)</time_frame>
    <description>Body Mass Index - (BMI; weight/height in kg/m2). Measurements will be taken in triplicate. Height will be measured to the nearest 0.5 cm with a stadiometer (or knee height, ulnar length or arm span [demispan] for those persons unable to stand fully erect); body weight will be measured to the nearest 0.1 kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurement</measure>
    <time_frame>Visit 6 (6 months after parasite treatment / intervention initiation)</time_frame>
    <description>Body Mass Index - (BMI; weight/height in kg/m2). Measurements will be taken in triplicate. Height will be measured to the nearest 0.5 cm with a stadiometer (or knee height, ulnar length or arm span [demispan] for those persons unable to stand fully erect); body weight will be measured to the nearest 0.1 kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurements</measure>
    <time_frame>Visit 7 (12 months after parasite treatment / intervention initiation)</time_frame>
    <description>Body Mass Index - (BMI; weight/height in kg/m2). Measurements will be taken in triplicate. Height will be measured to the nearest 0.5 cm with a stadiometer (or knee height, ulnar length or arm span [demispan] for those persons unable to stand fully erect); body weight will be measured to the nearest 0.1 kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurements</measure>
    <time_frame>Visit 8 (18 months after parasite treatment / intervention initiation)</time_frame>
    <description>Body Mass Index - (BMI; weight/height in kg/m2). Measurements will be taken in triplicate. Height will be measured to the nearest 0.5 cm with a stadiometer (or knee height, ulnar length or arm span [demispan] for those persons unable to stand fully erect); body weight will be measured to the nearest 0.1 kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurements</measure>
    <time_frame>Visit 9 (24 months after parasite treatment / intervention initiation)</time_frame>
    <description>Body Mass Index - (BMI; weight/height in kg/m2). Measurements will be taken in triplicate. Height will be measured to the nearest 0.5 cm with a stadiometer (or knee height, ulnar length or arm span [demispan] for those persons unable to stand fully erect); body weight will be measured to the nearest 0.1 kg.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Malnutrition</condition>
  <condition>Helminth Infection</condition>
  <arm_group>
    <arm_group_label>Malnourished without lung parasites</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thirty study participants, household contacts of an index TB case, who are malnourished and do not have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan.The consented household contact will also receive a daily multivitamin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malnourished with lung parasites</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thirty study participants, household contacts of an index TB case, who are malnourished and have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan. The consented household contact will also receive a daily multivitamin. These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Well-nourished with lung parasites</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Well-nourished without lung parasites</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These thirty study participants will serve as the control.These participants will be well-nourished and not have a parasite infection; therefore, they will not receive the nutritional supplementation or treatment for parasite infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutritional Supplementation Meal</intervention_name>
    <description>Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.</description>
    <arm_group_label>Malnourished with lung parasites</arm_group_label>
    <arm_group_label>Malnourished without lung parasites</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin</intervention_name>
    <description>Study participants will be given a daily multivitamin to take for 6 months.</description>
    <arm_group_label>Malnourished with lung parasites</arm_group_label>
    <arm_group_label>Malnourished without lung parasites</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-parasitic medications</intervention_name>
    <description>Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.</description>
    <arm_group_label>Malnourished with lung parasites</arm_group_label>
    <arm_group_label>Well-nourished with lung parasites</arm_group_label>
    <other_name>albendazole, ivermectin, metronidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Household Contacts

          -  Household contact that has been roommate of eligible index case for at least two of
             the previous four months (See index case criteria below).

          -  HIV seronegative

          -  Willing to be tested for pregnancy

          -  Age 18-55 years

          -  Willingness by the patient to attend scheduled follow-up visits and undergo study
             assessments

          -  Able to provide informed consent

        Exclusion Criteria: Household Contacts

          -  In the team's judgement, individual is not expected to survive for 12 months

          -  HIV infection or not willing to undergo HIV testing (if no documented HIV test)

          -  Pregnant at enrollment

          -  Known diabetes mellitus or evidence of diabetes on HA1C

          -  Xpert positive among those able to produce sputum

          -  TB symptoms (night sweats, weight loss, cough)

          -  Any history of TB disease during their lifetime

          -  We will retrospectively exclude household contacts of presumed TB cases whose cultures
             do not confirm Mtb or who are Xpert negative.

          -  Recall receiving anti-parasitic treatment within the past 6 months

          -  Evidence of kwashiorkor (pitting edema of foot or lower leg)

          -  Abnormal K, Mg, Phos in those with BMI &lt;16

        Inclusion Criteria: Index Case

          -  Sputum Ziehl-Neelsen stain positive for AFB (â‰¥1+)

          -  Culture or Xpert positive for Mtb; those who are smear+ but ultimately Xpert or
             culture negative, will be included until their culture results return at which time
             they will retrospectively be removed from the study.

          -  No history of TB treatment (i.e., no history of partial or complete treatment for a
             previous TB episode)

          -  Has at least 1 household contact with whom they have shared a room during the previous
             four months

          -  Agrees to have household contact notified about study

        Exclusion Criteria: Index Case

          -  No Xpert or culture confirmation and unable to provide sputum sample

          -  No household contacts who share room

          -  Known MDR or XDR TB case

          -  BMI &lt;16 kg/m2

          -  Lower extremity edema/kwashiorkor

          -  Reported neuropathy in lower extremities (may result from thiamine deficiency)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha Hochberg, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jawaharlal Institute of Postgraduate Medical Education and Research</name>
      <address>
        <city>Pondicherry</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood signature of Tb risk</keyword>
  <keyword>anti Mtb immunity</keyword>
  <keyword>RNA biomarkers</keyword>
  <keyword>RePORT Study</keyword>
  <keyword>India</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Helminthiasis</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Antiparasitic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

